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AddNeuroMedComputer-aided diagnosis of Alzheimer3s disease (AD) is a rapidly developing ﬁeld of neuroimaging with strong
potential to be used in practice. In this context, assessment of models3 robustness to noise and imaging protocol
differences together with post-processing and tuning strategies are key tasks to be addressed in order to move
towards successful clinical applications. In this study, we investigated the efﬁcacy of Random Forest classiﬁers
trained using different structural MRI measures, with and without neuroanatomical constraints in the detection
and prediction of AD in terms of accuracy and between-cohort robustness.
From The ADNI database, 185 AD, and 225 healthy controls (HC) were randomly split into training and testing
datasets. 165 subjects with mild cognitive impairment (MCI) were distributed according to the month of
conversion to dementia (4-year follow-up). Structural 1.5-TMRI-scanswere processed using Freesurfer segmen-
tation and cortical reconstruction. Using the resulting output, AD/HC classiﬁers were trained. Training included
model tuning and performance assessment using out-of-bag estimation. Subsequently the classiﬁers were vali-
dated on the AD/HC test set and for the ability to predict MCI-to-AD conversion.Models3 between-cohort robust-
ness was additionally assessed using the AddNeuroMed dataset acquired with harmonized clinical and imaging
protocols.
In the ADNI set, the best AD/HC sensitivity/speciﬁcity (88.6%/92.0%— test set) was achieved by combining corti-
cal thickness and volumetric measures. The Random Forest model resulted in signiﬁcantly higher accuracy com-
pared to the reference classiﬁer (linear Support Vector Machine). The models trained using parcelled and high-
dimensional (HD) input demonstrated equivalent performance, but the former was more effective in terms of
computation/memory and time costs. The sensitivity/speciﬁcity for detecting MCI-to-AD conversion (but not
AD/HC classiﬁcation performance) was further improved from79.5%/75%–83.3%/81.3% by a combination ofmor-
phometricmeasurementswith ApoE-genotype and demographics (age, sex, education).When applied to the in-
dependent AddNeuroMed cohort, the best ADNI models produced equivalent performance without substantial
accuracy drop, suggesting good robustness sufﬁcient for future clinical implementation.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.ucla.edu). As such, the investigatorswithin the
NI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can
how_to_apply/ADNI_Acknowledgement_List.pdf.
icine, Stavanger University Hospital, PO Box 8100, 4068 Stavanger, Norway.
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The application of pattern recognition approaches to neuroimaging
offers the potential for diagnostically relevant analysis techniques, in
particular for magnetic resonance imaging (MRI), which has already
been demonstrated to provide relevant support in the diagnosis of
Alzheimer3s disease (AD) (O3Brien, 2007). A large number of studies ad-
dressing the use of pattern recognition methods in image-based detec-
tion of AD have been published in recent years (Gray et al., 2013; Liu
et al., 2012; Cuingnet et al., 2011; Klöppel et al., 2008).
The advantage of these methods over visual assessment by a medi-
cal expert is that they are fully automated and therefore unbiased to-
wards human mistakes and can be incorporated into computerized
medical decision-support systems, a growing ﬁeld with especially fast
research progress in radiology (Stivaros et al., 2010; Belle et al., 2013).
However, suchmethods do have limitations. Our previous work dem-
onstrated that pattern recognition methods are sensitive to MR-protocol
differences (Westman et al., 2011; Lebedev et al., 2013) and that a harmo-
nization step is therefore required. Another relevant issue pertains to the
comparison of high-dimensional imaging data input versus measure-
ments extracted by neuroanatomical parcellation atlases, with the areas
separated according to functional and histological maps of the human
cortex (for simplicity, we will use the term “parcelled data”). Parcelled
input has someobvious advantages in terms of lower computation,mem-
ory cost and processing time. However, it is possible that it could be bi-
ased by these landmarks. Normalized high-dimensional measurements
without parcellation, in contrast, are unbiased, but at the same time are
more difﬁcult to handle using multivariate and machine learning ap-
proaches due to computation and memory costs. Moreover, situations
where the number of measurements is much larger than the number of
observations (p≫ n) are often associated with the so-called “curse of di-
mensionality” (Bellman, 1961). This refers to a number of events that
happen when dealing with high-dimensional input (due to increasing
sparsity of the data), signiﬁcantly hampering modeling efﬁcacy. Such
cases often require a preparatory step of dimensionality reduction.
Random Forest (RF) is an ensemble machine learning algorithm,
which is best deﬁned as a “combination of tree predictors such that
each tree depends on the values of a random vector sampled inde-
pendently and with the same distribution for all trees in the forest”
(Breiman, 2001).
Inmany applications this algorithmproduces one of the best accura-
cies to date and has important advantages over other techniques in
terms of ability to handle highly non-linear biological data, robustness
to noise, tuning simplicity (compared to other ensemble learning algo-
rithms) and opportunity for efﬁcient parallel processing (De Bruyn
et al., 2013; Caruana and Niculescu-Mizil, 2006; Menze et al., 2009).
These factors also make RF an ideal candidate for handling high-
dimensional problems, where the number of features is often redun-
dant. Although RF can itself be considered as an effective feature selec-
tion algorithm, several approaches for feature set reduction within
and outside the context of RF have been proposed to further improve
its performance (Tuv et al., 2009). In the current study, we use recursive
feature elimination (Kuhn, 2012a) to optimize the models.
Our previous work revealed that parcelled cortical thickness togeth-
er with subcortical volumetric measurements (used as an input to a
multivariate model) resulted in the best performance, compared to
other modalities (Westman et al., 2013). Here, we aimed not only to
assess the accuracies of the classiﬁers trained with different morpho-
metric modalities, but also to analyze the impact of dimensionality,
parcellation strategy on models3 accuracy, computation/memory/time
costs of model training and feature selection. Finally, previous studies
have successfully employed pattern recognition techniques to classifyMRI images from different cohorts only within the combined sets
(Westman et al., 2011; Lebedev et al., 2014). The present study was
planned as one of the ﬁrst to assess classiﬁers3 between-cohort robust-
ness in two independent large-scale datasets.
We hypothesized that with the use of more disease-speciﬁc
parcellation atlases (in this case, when themeasurements are extracted
from the predeﬁned regions, known to be affected by Alzheimer3s dis-
ease), it would be possible to achieve AD-detection accuracy equivalent
to that of the models trained with high-dimensional input without
parcellation with shorter computational time. In addition, we hypothe-
sized that it is possible to achieve good between-cohort generalization
of the models if the MRI protocols are harmonized.
2. Methods
2.1. Subjects
The study was based on two cohorts. The ﬁrst set of clinical andMRI
data was obtained from the Alzheimer3s Disease Neuroimaging Initia-
tive (ADNI-1) database (http://adni.loni.ucla.edu). In short, ADNI-1 in-
cludes more than 800 subjects with up to 5 years of annual follow-up
with comprehensive clinical, neuropsychological, imaging and laborato-
ry evaluations, performed at the 57 specialized ADNI sites in North
America. For details, see Aisen et al. (2010) and ADNI-Core (2011).
The present cross-sectional study is focused on baseline imaging data
and longitudinal information regarding conversion to dementia.
In total, 3D T1 baseline brain scans from 809 subjects passed
our image quality control criteria. From this group we selected
575 subjects – 185 AD, 225 healthy controls (HC) and 165 patients
with mild cognitive impairment (MCI) and long term follow up infor-
mation – who met the inclusion criteria (see below).
In order to test the impact of different cohorts, we additionally
included 321 subjects (AD 107, 114 MCI and 100 HCs) from the
AddNeuroMed study with harmonized clinical and imaging protocols
(http://www.innomed-addneuromed.com/). The standardized study har-
monization workﬂow (described in previous publications) particularly
included careful MR protocol alignment evaluated by phantom scan-
ning and careful quality control (Simmons et al., 2011).
2.2. Inclusion criteria and clinical assessment procedures
All ADpatientsmet theNINCDS/ADRDA criteria for probable AD, had
mild level of dementia, deﬁned as the Mini-Mental State Examination
(MMSE) score between 20 and 26, and had the Clinical Dementia Rating
(CDR) score of 1.0.
Inclusion criteria for MCI were: 1) MMSE score between 24 and 30,
2) memory complaints and objective memory impairment measured
by the Logical Memory II subscale of theWechsler Memory Scale (edu-
cation adjusted), 3) CDR of 0.5, 4) absence of signiﬁcant levels of impair-
ment in other cognitive domains, 5) preserved activities of daily living,
and 6) absence of dementia. MCI converters had to meet the criteria
for Alzheimer3s disease during at least two sequential evaluations
(e.g., at 24 and 36 month follow-ups). Those MCI subjects who did not
have the required follow-up information or had their diagnoses changed
back from AD to MCI (or to HC) were excluded (n = 232 out of 397). To
considerMCI subjects as beingnon-converterswe required that their clin-
ical status remained stable for at least 3 years of follow-up.
Controls (general inclusion/exclusion criteria): 1) MMSE scores
between 28 and 30, 2) CDR of 0, and 3) they did not meet the criteria
for clinical depression at baseline, MCI or dementia within 3 years of
follow-up. One HC subject (ID # 0223) was excluded from the sample
due to conversion to AD at follow-up. One AD subject (ID # 0805) was
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Subjects were between 55 and 90 years of age.
Apart from this, the standardized clinical evaluation protocol includ-
ed multi-test assessment of cognitive functions and neuropsychiatric
symptoms, ApoE genotyping and some other procedures (for more de-
tails see http://www.adni-info.org/).2.3. Subsampling
From the ﬁnal ADNI cohort of 575 subjects, 150 AD patients and
150 HCs were randomly selected, forming the training dataset, with
the remaining AD 35 and 75 HC (coupled with 165 MCI patients) sub-
jects included in the testing dataset.
MCI subjects were split into 6 subgroups according to the month of
MCI-to-AD conversion during 4 years of follow-up (6th-, 12th-, 18th-,
24th-, 36+th-month converters and non-converters).2.4. Study ethics
The studies were approved by the local Regional Committees for
Medical Research Ethics. All patients providedwritten consent to partic-
ipate in the study after the scheduled procedures had been explained in
detail to the patient and a caregiver. All subjectswerewilling and able to
undergo all study procedures including imaging and agreed to longitu-
dinal follow-up.2.5. MRI
All subjects had 1.5 Tesla T1 3D MRI images acquired using the har-
monized ADNI-1 protocol (Jack et al., 2008). For details visit http://adni.
loni.usc.edu.2.6. Image post-processing
Image processing was performed at one site: Centre for Neuroimag-
ing Sciences, IoP (KCL). Image quality controlwasperformedusing stan-
dardized procedures (Simmons et al., 2011; Simmons et al., 2009).
Next, the raw3DT1MRI data underwent processing for surface-based
cortex reconstruction and volumetric segmentation using the Freesurfer
image analysis software (http://surfer.nmr.mgh.harvard.edu/) version 5.1
installed on a CentOS4 x86_64 cluster. There are several rationales for
using Freesurfer in our study. Firstly, the surface-based registration ap-
proach incorporated into this software has been shown to have better re-
producibility compared to Laplacian- or Registration-based methods for
cortical thickness estimation (Clarkson et al., 2011). Secondly, this frame-
work provides a range of different kinds of surface-based and volumetric
measurements, as well as different parcellation atlases for extracting av-
eraged morphometric data. The steps of this processing are described in
detail elsewhere (Ségonne et al., 2007; Ségonne et al., 2004; Fischl and
Dale, 2000; Fischl et al., 1999; Dale et al., 1999; Sled et al., 1998).
The surface-based pipeline produced several morphometric mo-
dalities (cortical thickness, Jacobian maps, and sulcal depth). After the
Freesurfer steps, cortical models from each individual were registered
to a spherical atlas, providing matching across subjects, and ﬁnally
327,684 normalized measurements acquired for every subject were
concatenated into large matrices (one for each high-dimensional mor-
phometric modality).
41 volumetric measurements for all subjects were corrected for intra-
cranial volume (ICV) using linear modelling (removing linear effects of
ICV) and ﬁnally concatenated into an n-by-41 matrix that was used in
the subsequent analysis.
The image post-processing and analysis steps are illustrated in
Appendix: Fig. A1.2.7. Statistical analysis
Statistical analysis was carried out using the R programming lan-
guage (R Core Team, 2012), version 2.15.1, on R-Cloud built on EBI 64-
bit Linux Cluster (Kapushesky et al., 2010). Demographic and clinical
features were compared using parametric and non-parametric tests as
appropriate. Principal component analysis (PCA) from the R ‘base’ pack-
agewas usedwith visual inspection of PCA score-plot for the outlier de-
tection (Esbensen et al., 2002). One subject was excluded during this
procedure (see Results). The ‘randomForest’ package (Liaw and Wiener,
2002) was used in further analysis.2.8. Problem formulation
The Random Forest algorithm is formally deﬁned as a collection of
tree-structured classiﬁers: f(x,θk),k=1,2,…,K; where θk is a randomvector
that meets i.i.d. (independent and identically distributed) assumption
(Cover and Thomas, 2006) and each tree casts a unit vote for the most
popular class at input x (Breiman, 2001). For classiﬁcation problems, the
forest prediction is the unweighted plurality of class votes (majority
vote). The algorithm converges with a large enough number of trees.
For more detailed explanation see Breiman (2001).2.9. Parameter selection and classiﬁcation
The R package ‘caret’ (Kuhn, 2012a) was used to implement recur-
sive feature elimination (RFE) based on the Gini-criterion with 5-fold
cross-validation (CV) within the context of RF (Kuhn, 2012b). Each of
the steps described below was performed for all modalities: cortical
thickness, sulcal depth, Jacobianmaps, non-cortical volumes, combined
parcelledmeasurements of cortical thickness and non-cortical volumes.
First, the measurements with near-zero variance were removed from
the feature sets and the resulting output underwent stepwise RFE.
10,000 trees were used to “grow” the ﬁrst forest (using full feature
set), and afterwards RFE was performed based on feature importance
vector (deﬁned in Eq. 1) derived from the ﬁrst forest, by removing the
lowest-ranked 5% of the features at each step (gradually reducing the
dimensionality as 100%, 95%,… etc., up to 50%), and by the subsequent
accuracy comparison with 5-fold CV. In order to reduce CPU, RAM and
time usage the forests were trained with 1000 trees (instead of 10,000
for the ﬁrst forest) at each step of RFE. After selection of the optimal fea-
ture subset, mtry-parameter adjustment was also performed using 1000
trees (search range ∈ ½
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
N features
p
4 ;
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Nfeatures
p  2:5, step =
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
N features
p
4 ), and
ﬁnally the forests were retrained with optimal parameters using
10,000 trees. For the parcelled data (non-cortical volumes and
parcelled thickness), an exhaustive search for optimal feature subset
and mtry-parameter was performed, “growing” 1000 trees at each
step with 10-fold CV. See diagram in Appendix Fig. A2.
The following parameters from the ﬁnal models were reported to
characterize performance: out-of-bag error (for the term deﬁnition
see Breiman, 2001), area under the ROC curve (AUC), sensitivity/speci-
ﬁcity and overall accuracy on the testing datasets of AD, HC and MCI
subjects (see “Subsampling”). ROC-curves of the bestmodelswere com-
pared using DeLong3s test for two correlated ROCs, as implemented in
the ‘pROC’ R-package (Robin et al., 2011).
The robustness of eachmodel was also tested with respect to cohort
differences (using a different cohort of AD and HC subjects from the
AddNeuroMed study) (Simmons et al., 2011).
Finally, variables of importance were mapped from the best model
into the brain space in order to identify the regions, which were most
relevant for the classiﬁcation.
At every split node τ one of the mtry variables, say xk, is used to
form the split and there is a resulting decrease in the Gini index.
The mean decrease of the Gini index, ▵i(τ) (Eq. 1) was used as a
Table 1
Subject demographics: ADNI cohort.
AD HC MCIa AD/HC-comparison:
test (p-value)
N 185 225 165 −
Age 75.2 [±7.48] 75.95 [±5.02] 75.46 [±7.37] T = –1.17 (0.24)
M/F ratio 1.01 (93/92) 1.05 (115/110) 1.66 (103/62) χ2 = 0.01 (0.93)
Education 14.6 [±3.24] 16.0 [±2.85] 15.65 [±2.97] T = –4.65 (0.001)
MMSE 23.3 [±1.99] 29.1 [±0.98] 27.04 [±1.78] T = –35.5 (0.001)
a 149 of total 165MCI subjects developed Alzheimer3s disease at some point during the
4-year follow-up period (MCI-converters).
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ΔiðτÞ ¼ iðτÞ−ðpLiðτLÞ þ pRiðτRÞÞ ð1Þ
where iðτÞ ¼ 1−∑c∈Cp2c is the Gini index at node τ, pL ¼
jsLj j
js j j and
pR ¼
jsRj j
js j j are the probabilities of sending a data point to the left and
right nodes, respectively.
This metric reﬂects the contribution of a variable xk to the node ho-
mogeneity of τ. Thus, a higher mean decrease (Eq. 1) of the Gini index
for a particular feature means that the variable is present more often
in nodes with higher purity among all trees in the forest (overall). The
sum of all decreases in the forest due to a given variable xk, normalized
by the number of trees, therefore gives an estimate of its Gini impor-
tance (Eq. 2), i.e.:
IGðxkÞ ¼
1
ntree
∑
ntree
t¼1
∑
τ
Δixk ðτ; t Þ: ð2Þ
Therefore, the Gini importance IGðxkÞ indicates how frequent the
particular feature xk was selected in a split node, and how large its over-
all discriminative value was for the classiﬁcation task.
2.10. Morphometric modality combination
The classiﬁers trained with individual morphometric modality
were combined by a majority vote and subsequently compared
with the best model that demonstrated the highest accuracy (the
one trained using parcelled thickness and volumetric measure-
ments) on the test set.
We were also interested in assessing the effects of feature selection.
For this purpose, all the steps described above (in “Parameter selection
and classiﬁcation”) were performedwithout RFE (only mtry-parameter
adjustment). The resulting classiﬁers were assessed using the identical
approach and combined together by a majority vote.
2.11. Use of different parcellation schemes
To investigate the effect of different atlases, we selected cortical
thickness as a measurement type that produced the most accurate
models and applied two parcellations implemented in the Freesurfer
package – Desikan–Killiany (DK) and Destrieux (D) atlases – to extract
averaged values from the predeﬁned regions.
DK (Desikan et al., 2006) is a gyral-based neuroanatomical
parcellation atlas that subdivides each hemisphere of the human brain
cortex into 34 regions. One of the important features of this atlas,
which is especially relevant for the present study, is that it has been
developed using MRI scans not only from healthy controls (young,
middle- and old-age groups), but also from patientswith AD, and there-
fore this parcellationmay be considered asmore disease-speciﬁc. In ad-
dition, the atlas includes the entorhinal cortex as a separate region. This
area is a crucial element of the episodic memory system (Lipton and
Eichenbaum, 2008) and known to be affected by Alzheimer3s disease
from its initial stages (Braak and Braak, 1985).
The D atlas (Fischl et al., 2004; Destrieux et al., 2010) utilizes proba-
bilistic labeling algorithm and among its advantages is that it is not tied
to any speciﬁc neuroanatomical template, incorporating not only the
probable location of a region of interest, but also the potential inter-
subject variance of the location of the region (Fischl et al., 2004). This
parcellation includes more regions than the DK atlas (74 areas for
each hemisphere versus 34 in the DK atlas).
Next, after the training steps, we compared models3 performance
and ROC-curves as described above.2.12. Comparison with linear SVM
Apart from this, we compared our best models with “reference clas-
siﬁer”, linear support vectormachine (SVM) (Vapnik, 1995), tunedwith
recursive feature elimination. Of note, a non-linear SVMwas not used as
a reference, because it would be substantiallymore difﬁcult and compu-
tationally expensive to tune and therefore would not be a fair compari-
son in terms of computation and memory costs.
2.13. Combining imaging biomarkers with ApoE genotype and demographics
The ɛ-4 allele of the gene encoding Apolipoprotein E is one of the
major genetic risk factors for Alzheimer3s disease (Alonso Vilatela et al.,
2012). In order to investigate whether it was possible to further improve
the bestmodel (trained using combined cortical thickness and volumetric
measurements) information on subjects3 ApoE genotype (together with
demographics) was added as an additional feature. The resulting model
was trained and assessed as described above.
3. Results
3.1. Demographics
Themain demographic characteristics are described in Table 1. Signif-
icant differences between AD and HC subjects were observed in educa-
tion, in addition to word recall, ADAS-Cog andMMSE scores as expected.
Corresponding description of the AddNeuroMed cohort is provided
in Appendix Table A3.
3.2. Outlier detection
PCA-based outlier detection revealed one subject, whose Freesurfer
output was corrupted and was therefore excluded from the subsequent
analysis.
3.3. Classiﬁcation
Time andmemory costs of RFE andmtry-adjustment varied substan-
tially depending on the number of features. Thus, the total tuning time
varied between 10 min (volumetric data) and more than 89 h (Jacobian
maps). For all steps, from 6 to 10 CPU cores were used, and RAM usage
also varied signiﬁcantly between 1 Gigabyte (GB) (volumetric data)
and 58 GB (Jacobian maps). For details see Appendix Table. A4.
Among all models, three had the best competing performances
(Table 2, Fig. 1). The model trained using high-dimensional thickness
measurements demonstrated AD-detection sensitivity/speciﬁcity of
88.6%/90.7%, its out-of-bag AUC (95% C.I.) was 0.93 (0.9–0.96); while
the model trained using volumetric measurements resulted in sensitivity/
speciﬁcity = 82.9%/86.7%, AUC = 0.91 (0.88–0.95); and using parcelled
measurements of cortical thickness and subcortical structures resulted
in sensitivity/speciﬁcity = 88.6%/92.0%, AUC = 0.94 (0.91–0.96).
Comparing these 3modelswith the corresponding oneswithout RFE
revealed signiﬁcant (p b 0.001) advantages of RFE only for the model
trained with high-dimensional cortical thickness measurements. The
difference between the remaining two models was not signiﬁcant.
Table 2
AD/HC performance of the ﬁnal models: ADNI cohort.
Models OOB error
[Train]
Sensitivity/speciﬁcity
(OA) [Test]
AUC (95% C.I.)
Cortical thickness RFE 14.0% 88.6%/90.7% (89.62%) 0.93 (0.9–0.96)
Sulcal depth 21.3% 80.0%/74.7% (77.3%) 0.84 (0.8–0.89)
Jacobian 21.7% 77.1%/81.3% (79.2%) 0.84 (0.79–0.88)
Volumes 15.0% 82.9%/86.7% (84.7%) 0.91 (0.88–0.95)
Thickness +
volumes (ROI)
11.7% 88.6%/92.0% (90.3%) 0.94 (0.91–0.96)
Thickness no RFE 14.7% 88.6%/89.3% (89.0%) 0.92 (0.89–0.95)
Sulcal depth 14.0% 80.0%/73.3% (76.67%) 0.83 (0.79–0.88)
Jacobian 21.0% 80.0%/80.0% (80.0%) 0.84 (0.79–0.88)
Volumes 16.7% 80.0%/86.7% (83.3%) 0.91 (0.88–0.94)
Thickness +
volumes (ROI)
12% 85.7%/89.3% (87.5%) 0.93 (0.91–0.96)
AD/HC— Alzheimer3s disease/healthy controls; OA— overall accuracy; OOB — out-of-bag
estimate; AUC (95% C.I.) — area under the ROC curve with 95% conﬁdence interval.
Fig. 1.ROC curves:morphometricmodalities (AD/HC). The ﬁgure illustrates ROC-curves of
the models trained with different morphometric inputs. Three inputs demonstrate com-
peting performances: high-dimensional (HD) cortical thickness, volumetric data and com-
bined parcellated measurements. AD/HC— Alzheimer3s disease/healthy controls.
Fig. 2. Effect of cortical parcellation using DK and D atlases on AD/HC performance. ROC-
curves differed signiﬁcantly when compared to one from the model trained using non-
parcellated high-dimensional measurements (p-values: 0.002 and 0.009 — for Desikan-
Killiany (DK) and Destrieux (D), respectively) differences were non signiﬁcant between
DK and D. AD/HC — Alzheimer3s disease/healthy controls.
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(trained using parcelled measures of cortical thickness and volu-
metric data) with a corresponding SVM classiﬁer, revealed advan-
tages of the former. Test set AUCRF + RFE (95% C.I.) = 0.98 (0.96–1) and
AUCSVM + RFE (95% C.I.) = 0.93 (0.87–0.98). Although there was a slight
overlap between 95% C.I.s, further DeLong3s test revealed signiﬁcant
(p = 0.03) differences.
3.4. Combined models
Combining all models by a majority vote improved the overall accu-
racy (OA) to 91.0% (sensitivity/speciﬁcity=88.6%/93.3%— test set). The
ROC difference between the combined models with and without RFE
was signiﬁcant (p = 0.017). It did not, however, differ from the ROC of
the best classiﬁer trained using parcelled measurements of cortical
thickness and non-cortical volumes (see Appendix Fig. A5).
3.5. Effects of different parcellation schemes on classiﬁer performance
Use of the D parcellation atlas resulted in lower accuracy: test set
sensitivity/speciﬁcity/OA = 74.3%/82.7%/78.5% (compared to 82.9%/
88.0%/85.4% for the DK atlas). ROC differences between parcellations
[AUCs: 0.89 (0.85–0.93) and 0.90 (0.86–0.94), respectively] were non-
signiﬁcant. Both models demonstrated lower performance compared to
the one trained using non-parcelled measurements of cortical thickness
(sensitivity/speciﬁcity/OA = 88.6%/90.7%/89.6%, AUC = 0.93(0.9 −
0.96)). ROC differences (compared with “non-parcelled”models) were
signiﬁcant in both cases (p-values = 0.002 and 0.009, respectively).
Test set accuracies were, however, equivalent for the DK and atlas-free
measures. Results from this section are illustrated in Fig. 2.
3.6. Prediction of MCI-to-AD conversion
The best ability to predict MCI-to-AD conversion based on imaging
data only was observed for the model in which all RF ensembles were
combined by a majority vote, and was achieved at 76.6% in overall
MCI-to-AD conversion detection sensitivity, 2 years before actual de-
mentia onset (averaged value for 6th-, 12th-, 18th- and 24th-month
converters) with a speciﬁcity of 75.0% (see Table 3).
3.7. Combination with ApoE genotype and demographics
Adding ApoE genotype and demographics (age, sex, education) as
additional predictors into our best AD/HC model, trained using com-
bined cortical thickness and non-cortical volumetric measurements,
did not improve AD/HC classiﬁcation accuracy (sensitivity/speciﬁcity/
OA= 90.7%/82.9%/86.7%). Meanwhile, its accuracy for MCI-to-AD con-
versionwas relatively higher compared to othermodelswithmaximum
sensitivity/speciﬁcity/OA values of 83.3%/81.3%/82.3% (See Table 4).However, this improvement was not signiﬁcant with AUC for the
averaged group of the 2-year converters of 0.83 (0.7–0.965) in the
combined model versus AUC = 0.8(0.65− 0.95) for cortical thickness
alone (p = 0.74).
Table 3
Ability of the AD/HC models to predict MCI-to-AD conversion: morphometric data, ADNI cohort.
Measurements MCI-to-AD converters detection accuracya
6 m (n = 14) 12 m (n = 44) 18 m (n = 30) 24 m (n = 35) 36 m+ (n = 26) NC (n = 16)
Cortical thickness 78.6% 79.5% 70.0% 62.9% 65.3% 75.0%
Sulcal depth 71.4% 77.3% 53.3% 51.4% 53.8% 62.5%
Jacobian 60.2% 70.5% 76.7% 71.4% 53.8% 56.3%
Volumes 78.6% 72.7% 70.0% 68.6% 53.8% 75.0%
Combined 78.6% 79.5% 76.7% 71.4% 61.5% 75.0%
6, 12, 18, 24, 36 m+ —month of MCI-to-AD conversion; NC — non-converters (detected as HC by the classiﬁers); AD/HC — Alzheimer3s disease/healthy controls.
a Here the same models trained to classify images from AD and HC were used.
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Testing the ADNI models on AddNeuroMed data revealed good
generalizability of the classiﬁers. The best stability (both for AD
detection and prediction) was found for the models trained with
high-dimensional measures of cortical thickness and parcelled
thickness with volumetric measures. Combined models trained
using both imaging and non-imaging data demonstrated absence
of accuracy drop (see Table 5).
3.9. Regions of relevance
As expected, the observed pattern of feature relevance was typical for
AD and similar in models trained using high-dimensional and parcelled
input (Figs. 3 and4). It included atrophy in temporal areas (withmore ex-
tensive changes in the entorhinal cortex, hippocampus, and amygdala),
lateral ventricular size differences and parietal cortical abnormalities.4. Discussion
In the present study, we managed to produce robust and accurate
models with good generalization across different cohorts. Our classiﬁer
ensembles demonstrated one of the best AD detection and prediction
accuracy to date, superior over the reference model (linear SVM). It is
also worth noting that performance of the best ADNI models on the
AddNeuroMed dataset was equivalent to the cross-validated accuracies
reported in Westman3s study (Westman et al., 2011).
Of note, a recent study found no effect of the ApoE genotype on AD/
HC discrimination accuracy (Aguilar et al., 2013). This is in linewith our
results, which however demonstrated that adding this feature may beTable 4
MCI-c/MCI-nc performance of the combined model (morphometry + ApoE+ demographics).
OOB error AD: Sens/spec (test) MCI
6 m (n = 14) 12
Th + vol + ApoE+Age+Educ 11.3% 90.7%/82.9% (86.7%) 78.6% 75.
Th— cortical thickness; Vol— non-cortical volumes; Educ— education; MCI—mild cognitive im
Table 5
Classiﬁers’ performance in the same (ADNI) and separate (AddNeuroMed) cohorts.
Models AD: Sens/Spec (OA)
Same cohort (ADNI) Separate cohor
Thickness 88.6%/90.7% (89.62%) 87%/78% (82.5%
Sulcal Depth 80.0%/74.7% (77.3%) Failed
Jacobian 77.1%/81.3% (79.2%) 78.5%/72% (75.
Volumes 82.9%/86.7% (84.7%) 70.1%/89% (79.
Thickness + volumes (parc) 88.6%/92.0% (90.3%) 83.2%/89% (86.
Morphometry +ApoE +demographics 90.7%/82.9% (86.7%) 84.2%/88.3% (8
The classiﬁers were trained on the subset from the ADNI dataset and then validated on testing
Sens/Spec (OA) – Sensitivity/Speciﬁcity (Overall Accuracy);
* – for the AddNeuroMed cohort, deﬁnition of the MCI-to-AD converters subgroup (n=21) wa
NB: We did not compare accuracy to detect MCI non-converters due to only 1-year follow-upbeneﬁcial for detecting earlier stages of the disease (MCI-to-AD
converters).
To the best of our knowledge, this study is also one of the ﬁrst to in-
vestigate the impact of different parcellation schemes and dimensional-
ity of the imaging features on machine learning modeling accuracy,
computation/memory and time costs.
In our experiments, the use of a parcellation with more subregions
(148 versus 68) resulted in a drop in accuracy, which can be explained
by the fact that the Desikan–Killiany atlas provides more AD-speciﬁc
segmentation of temporal lobes compared to the Destrieux scheme,
extracting measurements from the entorhinal cortex (the cortical area
ﬁrst affected in AD). Therefore, the use of atlases providing segmentation
of the regions primarily affected by themost commonneurodegenerative
diseases may be beneﬁcial in such tasks. However, this is rather specu-
lative, since the atlases used in our study differ in many more aspects
than just availability of the disease-speciﬁc regions. Measurement-
speciﬁc parcellation schemes may also be useful for further accuracy
improvement.
We did not ﬁnd strong advantages for using high-dimensional input
over parcelledmeasurements for our classiﬁcation and prediction tasks.
Both inputs produced models with equivalent performance. It is worth
noting that tuning of the models with the parcelled input involved an
exhaustive search for the optimal feature subset and mtry-parameter,
whereas tuning of the HD-models was carried out only partially. There-
fore, we cannot be sure that exhaustive tuning of the HD-models would
not outperform the parcelled approach. But clarifying this currently
does not appear to be feasible and practically relevant, even given abun-
dant computational andmemory resources available for our study. Nev-
ertheless, it is worth mentioning that the use of high-dimensional raw
features may have advantages for certain tasks due to the absence of
spatial constraints of ROIs. Thus, we would generally expect thism (n = 44) 18 m (n = 30) 24 m (n = 35) 36 m+ (n = 26) NC (n = 16)
0% 83.3% 80.0% 50.0% 81.3%
pairment; ApoE— ApoE genotype; MCI-c/MCI-nc—MCI converters/MCI non-converters.
MCI-converter 1yr sensitivity*
t (AddNeuroMed) Same cohort (ADNI) Separate cohort (AddNeuroMed)
) 79.0% 76.2%
74.4% Failed
25%) 65.4% 57.1%
5%) 75.7% 57.1%
1%) 79.0% 71.4%
6.25%) 78.0% 79%
sets from both ADNI (same) and AddNeuroMed (separate) cohorts.
s deﬁned based on 1-year follow-up.
available for the AddNeuroMed cohort
Fig. 3. Cortical pattern of relevance for Alzheimer3s disease detection: high-dimensional morphometric data. The ﬁgure illustrates regions, which were the most relevant for Alzheimer3s
disease detection based on themean decrease of the Gini index (seeMethods). In all three high-dimensionalmodalities, the patternwas AD-speciﬁc and included changes predominantly
in temporal lobes (with maximum relevance of entorhinal region).
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not available.
In the present study, classiﬁers trained to differentiate between AD
and HC demonstrated a good ability to predict MCI-to-AD conversion
within 2 years before the onset of Alzheimer3s disease, which is in line
with previous results (Westman et al., 2012). The best accuracy was
observed for the classiﬁer produced by the combination of all
“high-dimensional”models with the model trained using non-cortical
volumetric measurements. Superior accuracy of this classiﬁer over the
model trained using parcelled data can be explained by the ability toFig. 4. Pattern of relevance for Alzheimer3s disease detection: parcelled morphometric data
(cortical thickness [DK-atlas] + non-cortical volumes). The ﬁgure illustrates regions, which
were the most relevant for Alzheimer3s disease detection based on the mean decrease of
the Gini index. Likewise in the high-dimensional input, the pattern-of-relevance is AD-
speciﬁc.detect less extensive structural changes, which are averaged in the
atlas-based parcellation.
Interestingly, a drop in the ability to predict MCI-to-AD conversion
over 6, 12, 18, 24 and 36+months was substantially steeper for cortical
thickness and sulcal depth compared to Jacobian maps, which demon-
strated relatively stable performance over 2 years. It can be speculated
that cortical thickness and sulcal depth aremore dynamicmeasures, in-
dicating disease progression, while Jacobian maps, as a geometric fea-
ture associated with cortical folding patterns, may be more genetically
determined and therefore more stable across lifespan. Thus, it has
been shown that geometric measures are associatedwith the formation
of neuronal connections and cortical connectivity patterns, serving as
characteristics of cerebral development (Armstrong et al., 1995; Van
Essen, 1997). However, further research is clearly needed to support
or reject this speculation.
Another interesting observation was that recursive feature elimina-
tion for the high-dimensional data improved performance of themodel
trained with cortical thickness, whereas other HD models did not seem
to demonstrate substantial improvement. A possible explanation for
this may be that the impact of neurodegeneration on cortical thickness
is more localized to the entorhinal area, whereas its impact on sulcal
depth and brain deformation is sparser, which complicates feature
elimination.
The main strengths of the present study are:
(a) the use of two large imaging databases of Alzheimer3s disease
with assessment of the classiﬁers3 between-cohort robustness;
(b) optimized models with one of the best accuracy to date;
(c) evaluation of several important factors inﬂuencing classiﬁcation
performance, such as morphometric data modality and dimen-
sionality, parcellation schemes;
(d) long-term follow-up available for the MCI subgroup from the
ADNI cohort that allowed the appropriate deﬁnition of MCI
non-converters and assessment ofmodels3 sensitivity at different
disease stages before the actual dementia onset.
It is also important to acknowledge several methodological limita-
tions, such as an inﬂuence of possible diagnostic mislabeling of the
data on our results, and possible misdiagnosis, since autopsy data
were not available. Therefore, without solving these issues one should
not expect perfect diagnostic class separation. The ﬁrst problem can
be addressed post-hoc by using computational approaches to detect
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more complex and pertains to the imperfection of diagnostic criteria
for AD,which can potentially be overcome by employingmore diagnos-
tic procedures (for example, dopamine transporter imaging to exclude
patients with Lewy body dementias), cerebrospinal ﬂuid markers, and
post-mortem diagnosis.
Another important issue pertains to robustness of the classiﬁers to the
MR-protocol differences. Clinical implementation of suchmodels will still
require additional reliability assessment in order to make sure that
models3 between-cohort generalization is appropriate. Apart from this,
traditional “ofﬂine” or “batch” learning framework (used in our study,
where the whole training set is available to the algorithm at the begin-
ning) does not allow any modiﬁcations of the models after the training
has been completed. The latter would be very relevant especially for the
clinical setting where continuous data ﬂow is usually available. The “on-
line” learning framework (where the system gradually “learns” using
one instance at a time) may be beneﬁcial in this context, providing not
only an opportunity to update the models, but also valid estimations of
the prediction conﬁdence under a general i.i.d. assumption (independent
and identically distributed) (Vovk, 2005; Gammerman and Vovk, 2007;
Nouretdinov and Lebedev, 2013). Since this approach can be applied to
an individual patient and gives reliable estimations of possible diagnoses,
it has strong potential to be used in clinical practice and, to our opinion,
would be the best candidate for diagnostic trials employing computer-
aided medical decision-support systems.
To conclude, our workﬂow produces accurate models for detec-
tion and prediction of AD with good between-cohort robustness.
The use of raw high-dimensional measurements does not appear to
be effective due to its high computation/memory costs and at the
same time equivalent performance compared to models trained
with parcelled input. Therefore, we recommend using disease-
speciﬁc parcellation schemes for image classiﬁcation tasks. Combi-
nation with other imaging and non-imaging biomarker modalitiesFig. A1.Workﬂow diagram. The diagram illustrates main steps of image post-processing and a
dimensionalmeasurements using Freesurfer software (blue box). After this part had completed,
used in further Random Forest classiﬁcation runs (in R programming language — gray box). W
adjustment (which deﬁnes the number of predictors randomly sampled at each node of the cla
the brain space (for the high-dimensional data) or plotted (for the parcelled input).
Appendixmay provide further improvement in accuracy and model
robustness.
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(5) the forests were retrained with optimal parameters using 10,000 trees.
Table A3
AddNeuroMed cohort demographics.
AD HC MCIa
N 107 100 114
Age 75.7 [±5.63] 73.2 [±6.87] 74.4 [±5.79]
M/F ratio 0.65 (42/65) 1.08 (52/48) 1.11 (60/54)
Education 7.6 [±3.78] 8.59 [±4.17] 10.5 [±4.82]
MMSE 20.8 [±4.74] 29.1 [±1.26] 27.1 [±1.68]
a 21 of total 114 MCI subjects developed Alzheimer3s disease at some point over 1-year follow-up. (MCI-converters)
Table A4
Model tuning.
Measurement NZV Feature subset after RFE Opt mtry CPU cores used RAM usage (RFE/mtry) Total tuning time
Thickness (HD) 14,880 156,402 356 6 51.3/44 GB 80 h 50 min
Sulcal depth (HD) 14,851 218,983 1170 6 51/46 GB 84 h 22 min
Jacobian (HD) 0 262,147 1024 6 58/45 GB 89 h 27 min
Volumes (ROI)a 0 6 2 10 1 GB 10 min
Thickness + volumes (parc)a 0 24 4 10 3.8 GB 3 h 35 min
NZV— number of features with Near-Zero Variance removed at the ﬁrst step; RFE — Recursive Feature Elimination; opt mtry — optimal mtry-parameter (see Methods for details).
a For these models, an exhaustive search for optimal mtry parameter and feature subset has been performed.
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Fig. A5. ROC curves: best models (AD/HC). The ﬁgure illustrates ROC-curves of the most accurate models trained to differentiate between AD and HC. The model trained using combined
parcelled (DK atlas) cortical thickness measures and subcortical volumetric data produced equivalent accuracy compared to the higher-order ensemble model (where all classiﬁers were
combined together by a majority vote). AD/HC — Alzheimer3s Disease/Healthy Controls.
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